Related Experiment Video

Updated: Jul 11, 2026

Detection of Anti-MDA5 Autoantibodies Using HeLa Cells and Immunocytochemistry with Light Microscopy
10:55

Detection of Anti-MDA5 Autoantibodies Using HeLa Cells and Immunocytochemistry with Light Microscopy

Published on: October 31, 2025

Clinical and serological follow-up of 71 patients with anti-mitochondrial type 5 antibodies

S Andrejevic1, B Bonaci-Nikolic, M Sefik-Bukilica

  • 1Institute of Allergy and Clinical Immunology, Clinical Center of Serbia, Koste Todorovica 2, Belgrade 11000, Serbia. s.andrej@sezampro.yu

Lupus
|September 27, 2007
PubMed

Insights

Antimitochondrial M5 antibodies (AMA M5) are linked to antiphospholipid syndrome (APS) and thrombocytopenia. Patients with AMA M5 require careful monitoring for APS development and screening for other hematological disorders.

Area of Science:

  • Immunology
  • Hematology
  • Rheumatology

Background:

  • Antimitochondrial M5 type antibodies (AMA M5) are associated with antiphospholipid syndrome (APS), thrombocytopenia, and autoimmune hemolytic anemia.
  • Understanding the clinical and immunological profile of AMA M5 is crucial for patient management.

Purpose of the Study:

  • To describe the clinical and immunological characteristics of patients with AMA M5.
  • To compare AMA M5 patients with a control group to identify distinct features.

Main Methods:

  • Analysis of 71 consecutive patients with AMA M5 over 8 years.
  • Comparison of clinical and immunological data with 70 consecutive disease control patients without AMA M5.

Main Results:

  • AMA M5 positive patients showed a higher prevalence of false positive VDRL tests and thrombocytopenia compared to controls.
  • Lower levels of anti-beta2 glycoprotein I antibodies were observed in AMA M5 patients.
  • Among AMA M5 patients, 38% met Sapporo criteria for APS, with 77.5% meeting laboratory criteria and 43.7% meeting clinical criteria.

Conclusions:

  • Younger patients with AMA M5 need close observation for APS development, even without serological criteria.
  • Elderly patients with AMA M5 should be screened for monoclonal gammopathy and hematological disorders.
  • AMA M5 is associated with a heterogeneous group of disorders, including a significant proportion of APS cases.

Related Concept Videos

Myocarditis II: Clinical Features and Diagnostic Tests01:27

Myocarditis II: Clinical Features and Diagnostic Tests

Myocarditis is an inflammation of the heart muscle. The symptoms vary widely, encompassing asymptomatic presentations to severe, acute manifestations.Clinical PresentationAsymptomatic cases: In some instances, myocarditis may be asymptomatic, with the infection resolving without intervention. These cases often go undetected unless discovered incidentally through diagnostic imaging or tests conducted for other reasons.General Early Symptoms: Early symptoms of myocarditis are non-specific and can...
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...